Table 4.

Participation, passing quota and laboratory performance in the external quality assurance program EQA250 for anti-C1-inhibitor autoantibodies.

Laboratory	2016	2017	2018	2019	2020	2021	2022	Performance	Participation, total
	IgG
1								57%	7
2								20%	5
3								50%	4
4								0%	2
5								0%	1
6								57%	7
7								71%	7
8								100%	3
9								100%	1
10								17%	6
11								100%	2
12								100%	1
13								100%	2
Passing quota	42.9%	42.9%	85.7%	83.3%	42.9%	42.9%	42.9%
Participation, total	7	7	7	6	7	7	7
	IgA
1								100%	7
2								100%	5
3								100%	4
4									0
5								100%	1
6								100%	7
7								100%	7
8								100%	3
9								100%	1
10								100%	5
11									0
12								100%	1
13								50%	2
Passing quota	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	83.3%
Participation, total	7	6	6	6	7	5	6
	IgM
1								86%	7
2								80%	5
3								75%	4
4									0
5								100%	1
6								100%	7
7								86%	7
8								0%	1
9								100%	3
10								60%	5
11									0
12								100%	1
13								50%	2
Passing quota	85.7%	83.3%	100.0%	83.3%	85.7%	80.0%	50.0%
Participation, total	7	6	6	6	7	5	6

Participation: Number of submitted results in the period of 2016-2022. Performance: Percentage of submitted results in the target range for both of the samples (dark blue).Any result out of target range (light red), lack of results (white). Passing quota: Performance of laboratories in the indicated years. Bold facing: laboratories with at least four participations and at least 80% performance. Laboratory numbers in the three parts of the table indicate the same participants.